Preclinical studies of cytotoxicity and cytostatic activity of five new imidazotriazine derivatives in MDA-MB231, BT474, and MCF-7 breast cancer cell cultures
Preclinical analysis reveals cytotoxicity and cytostatic activity of imidazotriazine compounds against breast cancer cells, indicating potential for further study.
Key Points
Imidazotriazine 1 exhibited the highest cytotoxic activity with an IC50 of 1.94 mmol/L, suggesting strong antitumor potential.
The preclinical study compared five new imidazotriazine derivatives, where only derivatives 4 and 5 surpassed the comparator drug temozolomide in activity.
Assessment involved testing cytotoxic and cytostatic activities in MDA-MB231, BT474, and MCF-7 breast cancer cell cultures at varying concentrations.
These results may enable the development of new treatments for patients who often experience inadequate therapy due to drug resistance.